Factorial Partners LLC Cuts Stock Position in Solventum Corporation $SOLV

Factorial Partners LLC lessened its stake in Solventum Corporation (NYSE:SOLV) by 22.6% in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 32,500 shares of the company’s stock after selling 9,500 shares during the quarter. Solventum makes up about 1.7% of Factorial Partners LLC’s portfolio, making the stock its 25th biggest holding. Factorial Partners LLC’s holdings in Solventum were worth $2,575,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Assetmark Inc. increased its holdings in Solventum by 21.4% in the 4th quarter. Assetmark Inc. now owns 725 shares of the company’s stock worth $57,000 after acquiring an additional 128 shares in the last quarter. Hilltop National Bank boosted its stake in Solventum by 71.3% during the 4th quarter. Hilltop National Bank now owns 310 shares of the company’s stock worth $25,000 after purchasing an additional 129 shares during the last quarter. Allworth Financial LP boosted its stake in Solventum by 2.8% during the 3rd quarter. Allworth Financial LP now owns 4,788 shares of the company’s stock worth $350,000 after purchasing an additional 129 shares during the last quarter. CIBC Private Wealth Group LLC boosted its stake in Solventum by 0.5% during the 3rd quarter. CIBC Private Wealth Group LLC now owns 24,710 shares of the company’s stock worth $1,804,000 after purchasing an additional 134 shares during the last quarter. Finally, BOKF NA boosted its stake in Solventum by 6.9% during the 3rd quarter. BOKF NA now owns 2,193 shares of the company’s stock worth $160,000 after purchasing an additional 141 shares during the last quarter.

Solventum Price Performance

NYSE:SOLV opened at $75.97 on Tuesday. Solventum Corporation has a 52 week low of $62.38 and a 52 week high of $88.20. The stock’s fifty day moving average is $69.75 and its two-hundred day moving average is $75.08. The company has a market capitalization of $13.16 billion, a P/E ratio of 9.31, a P/E/G ratio of 1.16 and a beta of 0.59. The company has a quick ratio of 0.75, a current ratio of 1.07 and a debt-to-equity ratio of 0.96.

Solventum (NYSE:SOLV) last released its quarterly earnings results on Tuesday, May 5th. The company reported $1.48 earnings per share for the quarter, topping analysts’ consensus estimates of $1.35 by $0.13. The business had revenue of $2.01 billion during the quarter, compared to analysts’ expectations of $1.97 billion. Solventum had a return on equity of 23.51% and a net margin of 17.33%.The company’s revenue was down 3.0% compared to the same quarter last year. During the same period in the prior year, the business posted $1.34 EPS. Solventum has set its FY 2026 guidance at 6.600-6.600 EPS. Equities analysts expect that Solventum Corporation will post 6.58 EPS for the current year.

Analyst Ratings Changes

Several equities research analysts have issued reports on the stock. BTIG Research reaffirmed a “buy” rating and set a $89.00 target price on shares of Solventum in a research note on Wednesday, May 6th. Wells Fargo & Company lowered their target price on shares of Solventum from $83.00 to $70.00 and set an “equal weight” rating on the stock in a research note on Wednesday, May 6th. KeyCorp lifted their target price on shares of Solventum from $92.00 to $93.00 and gave the stock an “overweight” rating in a research note on Wednesday, May 6th. Piper Sandler lowered their target price on shares of Solventum from $98.00 to $92.00 and set an “overweight” rating on the stock in a research note on Friday, April 17th. Finally, Rothschild & Co Redburn assumed coverage on shares of Solventum in a research note on Tuesday, March 24th. They set a “sell” rating and a $60.00 target price on the stock. Eight research analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $84.25.

Insiders Place Their Bets

In related news, Director Amy Mcbride Wendell purchased 1,475 shares of the company’s stock in a transaction on Tuesday, March 10th. The stock was acquired at an average cost of $68.03 per share, for a total transaction of $100,344.25. Following the completion of the transaction, the director directly owned 5,039 shares in the company, valued at approximately $342,803.17. The trade was a 41.39% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is available at this link. 0.24% of the stock is currently owned by company insiders.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.